MA37691A1 - 5-amino[1,4]thiazines comme inhibiteurs de bace1 - Google Patents

5-amino[1,4]thiazines comme inhibiteurs de bace1

Info

Publication number
MA37691A1
MA37691A1 MA37691A MA37691A MA37691A1 MA 37691 A1 MA37691 A1 MA 37691A1 MA 37691 A MA37691 A MA 37691A MA 37691 A MA37691 A MA 37691A MA 37691 A1 MA37691 A1 MA 37691A1
Authority
MA
Morocco
Prior art keywords
thiazines
amino
bace1 inhibitors
present
compounds
Prior art date
Application number
MA37691A
Other languages
English (en)
Other versions
MA37691B1 (fr
Inventor
Hans Hilpert
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA37691A1 publication Critical patent/MA37691A1/fr
Publication of MA37691B1 publication Critical patent/MA37691B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule i présentant une activité inhibitrice de bace1, leur préparation, des compositions pharmaceutiques les contenant et leur utilisation comme substances thérapeutiquement actives. Les composés actifs de la présente invention sont utiles dans le traitement thérapeutique et/ou prophylactique de, par exemple, la maladie d'alzheimer.
MA37691A 2012-05-24 2014-12-24 5-amino[1,4]thiazines comme inhibiteurs de bace1 MA37691B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12169353 2012-05-24
PCT/EP2013/060352 WO2013174781A1 (fr) 2012-05-24 2013-05-21 5-amino[1,4]thiazines comme inhibiteurs de bace1

Publications (2)

Publication Number Publication Date
MA37691A1 true MA37691A1 (fr) 2016-03-31
MA37691B1 MA37691B1 (fr) 2016-11-30

Family

ID=48534350

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37691A MA37691B1 (fr) 2012-05-24 2014-12-24 5-amino[1,4]thiazines comme inhibiteurs de bace1

Country Status (21)

Country Link
US (1) US9273042B2 (fr)
EP (1) EP2855469B1 (fr)
JP (1) JP6251249B2 (fr)
KR (1) KR20150014934A (fr)
CN (1) CN104334554B (fr)
AU (1) AU2013265376B2 (fr)
BR (1) BR112014028813A2 (fr)
CA (1) CA2872179A1 (fr)
CL (1) CL2014003123A1 (fr)
CO (1) CO7131369A2 (fr)
CR (1) CR20140495A (fr)
EA (1) EA026004B1 (fr)
IL (1) IL235681A (fr)
MA (1) MA37691B1 (fr)
MX (1) MX2014013839A (fr)
NZ (1) NZ702254A (fr)
PE (1) PE20150021A1 (fr)
PH (1) PH12014502541A1 (fr)
SG (1) SG11201407575PA (fr)
UA (1) UA113438C2 (fr)
WO (1) WO2013174781A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103874496A (zh) * 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
WO2014059185A1 (fr) 2012-10-12 2014-04-17 Amgen Inc. Composés amino-dihydrothiazine et amino-dioxydo dihydrothiazine en tant qu'antagonistes de bêta-sécrétase et procédés d'utilisation
WO2015017407A1 (fr) 2013-07-30 2015-02-05 Amgen Inc. Composés de dioxyde d'amino-thiazine bicycliques pontés en tant qu'inhibiteurs de bêta-sécrétase
WO2015038446A1 (fr) * 2013-09-13 2015-03-19 Merck Sharp & Dohme Corp. Dioxydes d'iminothiazine spiro-c5 utilisés comme inhibiteurs de bace, compositions, et leur utilisation
EP3215514B1 (fr) * 2014-11-03 2018-11-21 F. Hoffmann-La Roche AG Inhibiteurs de bace1
EP3271355B1 (fr) * 2015-03-20 2020-07-29 H. Hoffnabb-La Roche Ag Inhibiteurs de bace1
JP6895424B2 (ja) * 2015-08-12 2021-06-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害剤
AU2019258575A1 (en) 2018-04-27 2020-10-29 Shionogi & Co., Ltd. Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity
CN110467611B (zh) * 2018-05-11 2022-09-27 广东东阳光药业有限公司 亚氨基噻二嗪二氧化物衍生物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008516945A (ja) * 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ化合物およびそれらの使用
US8461160B2 (en) * 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
US20110065695A1 (en) * 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
BR112013026341A2 (pt) * 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
CN103874496A (zh) * 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途

Also Published As

Publication number Publication date
UA113438C2 (xx) 2017-01-25
CA2872179A1 (fr) 2013-11-28
CL2014003123A1 (es) 2015-02-27
HK1201261A1 (en) 2015-08-28
MA37691B1 (fr) 2016-11-30
CN104334554A (zh) 2015-02-04
EP2855469A1 (fr) 2015-04-08
KR20150014934A (ko) 2015-02-09
EP2855469B1 (fr) 2019-06-19
NZ702254A (en) 2016-08-26
US9273042B2 (en) 2016-03-01
CO7131369A2 (es) 2014-12-01
CN104334554B (zh) 2017-10-31
IL235681A0 (en) 2015-02-01
MX2014013839A (es) 2015-02-04
CR20140495A (es) 2014-12-01
PH12014502541B1 (en) 2015-01-21
IL235681A (en) 2017-10-31
PH12014502541A1 (en) 2015-01-21
JP6251249B2 (ja) 2017-12-20
BR112014028813A2 (pt) 2017-06-27
US20150141413A1 (en) 2015-05-21
WO2013174781A1 (fr) 2013-11-28
AU2013265376A1 (en) 2014-11-13
PE20150021A1 (es) 2015-01-28
EA201492097A1 (ru) 2015-04-30
EA026004B1 (ru) 2017-02-28
JP2015517548A (ja) 2015-06-22
AU2013265376B2 (en) 2017-07-20
SG11201407575PA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2
MA38556A1 (fr) Inhibiteurs de bace1
MA35246B1 (fr) 1,3-oxazines en tant qu'inhibiteurs de bace1 et/ou de bace2
MA35191B1 (fr) Spiro-[1,3]-oxazines et spiro-[1,4]-oxazepines en tant qu'inhibiteurs de baec1 et/ou bace2
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA35114B1 (fr) 1,3-oxazines à titre d'inhibiteurs de bace1 et/ou de bace2
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA35576B1 (fr) Nouveaux composés
MX2013008478A (es) 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2).
MA52370B1 (fr) Dérivés de la pyridine et leurs utilisations thérapeutiques comme inhibiteurs du trpc6
MA38473B1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
MA39260A1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c
MA38280B1 (fr) Composes 1,2,3,4-tetrahydroisoquinoleine substitues inhibiteurs de la proteine arginine-methyltransferase 5